# Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score

Study · id `cardio:ct-nct03386539` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03386539](<https://clinicaltrials.gov/study/NCT03386539>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03386539

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 211 participants.

## Technical summary

Registry record NCT03386539. Randomized; single masking; primary purpose treatment. Start 2018-01-29 (actual); primary completion 2023-04-17 (actual). Results posted on 2026-07-31.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 211 participants (enrolled count; ClinicalTrials.gov record NCT03386539, source copy `cardio:ctgov-nct03386539-2026-07-31`, retrieved 2026-10-26)
- Started: 2018-01-29 (actual) (ClinicalTrials.gov record NCT03386539, source copy `cardio:ctgov-nct03386539-2026-07-31`, retrieved 2026-10-26)
- Primary completion: 2023-04-17 (actual) (ClinicalTrials.gov record NCT03386539, source copy `cardio:ctgov-nct03386539-2026-07-31`, retrieved 2026-10-26)
- Completion: 2023-05-17 (actual) (ClinicalTrials.gov record NCT03386539, source copy `cardio:ctgov-nct03386539-2026-07-31`, retrieved 2026-10-26)
- Results first posted: 2026-07-31 (ClinicalTrials.gov record NCT03386539, source copy `cardio:ctgov-nct03386539-2026-07-31`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03386539, source copy `cardio:ctgov-nct03386539-2026-07-31`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03386539-2026-07-31`, retrieved 2026-10-26)

## The registry's words

- Brief title: Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score
- Acronym: TEAMMATE
- Condition: Pediatric Heart Transplantation
- Condition: Immunosuppression
- Condition: Chronic Kidney Diseases
- Condition: Cardiac Allograft Vasculopathy
- Condition: Heart Transplant Failure and Rejection
- Condition: Post-transplant Lymphoproliferative Disorder
- Condition: Heart Transplant Infection
- Intervention (Drug): Everolimus
- Intervention (Drug): Tacrolimus
- Intervention (Drug): Mycophenolate Mofetil
- Lead sponsor: Boston Children's Hospital
- Lead sponsor class: OTHER
- Collaborator: Stanford University
- Collaborator class: OTHER
- Collaborator: United States Department of Defense
- Collaborator class: FED

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Boston Children's Hospital (`cardio:org-boston-children-s-hospital`)
- Registry lists this organization as a collaborator: Stanford University (`cardio:org-stanford-university`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Everolimus and Low-Dose Tacrolimus After Heart Transplant in Children: A Randomized Clinical Trial (`cardio:pubmed-40960806`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 38efecc9b57fa942cd90d44e1ea4054c4eea55f819f5ad654d69730d484f3114
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
